These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36249772)

  • 41. Community pharmacists' knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, Saudi Arabia.
    Khan TM
    Ther Adv Drug Saf; 2013 Apr; 4(2):45-51. PubMed ID: 25083250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study.
    Ahmad A; Patel I; Balkrishnan R; Mohanta GP; Manna PK
    Perspect Clin Res; 2013 Oct; 4(4):204-10. PubMed ID: 24312887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors associated with spontaneous adverse drug reaction reporting among healthcare professionals in Vietnam.
    Le TT; Nguyen TTH; Nguyen C; Tran NH; Tran LA; Nguyen TB; Nguyen N; Nguyen HA
    J Clin Pharm Ther; 2020 Feb; 45(1):122-127. PubMed ID: 31486525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Knowledge of and attitudes about adverse drug reaction reporting among Rhode Island pharmacists.
    Generali JA; Danish MA; Rosenbaum SE
    Ann Pharmacother; 1995 Apr; 29(4):365-9. PubMed ID: 7633012
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hospital pharmacists' roles and attitudes in providing information on the safety of non-steroidal anti-inflammatory drugs in Thailand.
    Phueanpinit P; Jarernsiripornkul N; Pongwecharak J; Krska J
    Int J Clin Pharm; 2014 Dec; 36(6):1205-12. PubMed ID: 25288144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hospital pharmacists' activities and attitudes regarding the Thai safety monitoring program for new drugs.
    Jarernsiripornkul N; Krska J; Pongmanachai M; Nasritha N
    Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):837-41. PubMed ID: 19548223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Knowledge, Attitude and Practice of Hospital Pharmacists in Central China Towards Adverse Drug Reaction Reporting: A Multicenter Cross-Sectional Study.
    Hu W; Tao Y; Lu Y; Gao S; Wang X; Li W; Jiang Q; Lin L; Sun F; Cheng H
    Front Pharmacol; 2022; 13():823944. PubMed ID: 35392558
    [No Abstract]   [Full Text] [Related]  

  • 48. ADVERSE DRUG REPORTING IN COMMUNITY PHARMACY PRACTICE IN THE POMERANIAN DISTRICT IN POLAND.
    Zimmermann A; Gaworska-Krzeminska A; Flis A
    Acta Pol Pharm; 2016 Sep; 73(5):1389-1396. PubMed ID: 29638080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacovigilance and Adverse Drug Reactions Reporting: Healthcare Providers' Experiences from Southern Highland Tanzania.
    Mwakawanga DL; Kilonzi M; Philipo EG; Martine A; Mbilinyi T; Kileo NF; Mkinga B; Shonyella CJ; Mohamedi JA; Clement A; Mwasomola D; Mushy SE; Sirili N
    Adv Pharmacol Pharm Sci; 2023; 2023():5537592. PubMed ID: 37876921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals.
    Rehan HS; Chopra D; Holani SN; Mishra R
    Int J Risk Saf Med; 2014; 26(1):1-8. PubMed ID: 24796346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacists' attitudes towards the reporting of suspected adverse drug reactions in Norway.
    Granas AG; Buajordet M; Stenberg-Nilsen H; Harg P; Horn AM
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):429-34. PubMed ID: 16953518
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adverse drug reaction reporting quality among different health professionals and the contribution of clinical pharmacists: A pilot study.
    Yan J; Xiong X; Shen J; Huang T
    J Clin Pharm Ther; 2022 Nov; 47(11):1768-1774. PubMed ID: 35781820
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A cross sectional pilot study on assessing the knowledge, attitude and behavior of community pharmacists to adverse drug reaction related aspects in the Sultanate of Oman.
    Jose J; Jimmy B; Al-Ghailani AS; Al Majali MA
    Saudi Pharm J; 2014 Apr; 22(2):163-9. PubMed ID: 24648829
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Knowledge, attitude and practices of pharmacovigilance and adverse drug reaction reporting among pharmacists working in secondary and tertiary governmental hospitals in Kuwait.
    Alsaleh FM; Alzaid SW; Abahussain EA; Bayoud T; Lemay J
    Saudi Pharm J; 2017 Sep; 25(6):830-837. PubMed ID: 28951666
    [No Abstract]   [Full Text] [Related]  

  • 55. Improved reporting of adverse drug reactions.
    Kimelblatt BJ; Young SH; Heywood PM; Mandala AR; Gendelman S; Mehl B
    Am J Hosp Pharm; 1988 May; 45(5):1086-9. PubMed ID: 3400650
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Knowledge, attitudes and practices of nurses and pharmacists towards adverse drug reaction reporting in the South African private hospital sector.
    Bogolubova S; Padayachee N; Schellack N
    Health SA; 2018; 23():1064. PubMed ID: 31934371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Barriers and facilitators to pharmacovigilance activities in Pakistan: A healthcare professionals-based survey.
    Hussain R; Akram T; Hassali MA; Muneswarao J; Rehman AU; Hashmi F; Babar ZU
    PLoS One; 2022; 17(7):e0271587. PubMed ID: 35905133
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Knowledge, attitudes, and perceptions of pharmacists to adverse drug reaction reporting in Iran.
    Vessal G; Mardani Z; Mollai M
    Pharm World Sci; 2009 Apr; 31(2):183-7. PubMed ID: 19116770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of hospital and community pharmacists in pharmacovigilance.
    van Grootheest AC; de Jong-van den Berg LT
    Res Social Adm Pharm; 2005 Mar; 1(1):126-33. PubMed ID: 17138470
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spontaneous adverse drug reaction reporting by community pharmacists: preparedness and barriers.
    Bahlol M; Bushell M; Khojah HMJ; Dewey RS
    Saudi Pharm J; 2022 Jul; 30(7):1052-1059. PubMed ID: 35903525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.